Total Funding
37
Total FundingVenture - Series Unknown raised
Growth Score
pts
Heat Score
-24 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
Radimmune Therapeutics is an early stage biotechnology company that pioneers innovative therapies.
- Steven Deitcher: President, CEO, and Board MemberPast Role: Medeor Therapeutics, Co-Founder, CEO and President
- David Rickles: Co-founder and Chief Scientific Officer
About the Company
Radimmune Therapeutics is an early-stage biotechnology company that pioneers innovative therapies. It develops antibody-targeted radiation therapeutics, also known as radioimmunotherapy and liquid radiation. An alpha-emitting and/or beta-emitting radioisotope is guided to a universal target antigen. Radimmune has developed proprietary
antibodies targeting extracellular accumulations of, normally, intracellular substances.
Since its inception, the Radimmune Therapeutics has been driven by the belief that additional tools are needed for the fight against cancer. To that end, Radimmune Therapeutics has developed proprietary technology and platform focused on the most challenging to treat cancers.
It is based in Burlingame, California.
